Cargando…

Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker

BACKGROUND: Belonging to the protein arginine methyltransferase (PRMT) family, the enzyme encoded by coactivator associated arginine methyltransferase 1 (CARM1) catalyzes the methylation of protein arginine residues, especially acts on histones and other chromatin related proteins, which is essentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Yingqi, Wang, Hao, Liao, Peiyun, Xu, Binyan, Hu, Rong, Yang, Yulu, Li, Yuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761291/
https://www.ncbi.nlm.nih.gov/pubmed/35033016
http://dx.doi.org/10.1186/s12863-021-01022-w
_version_ 1784633497054347264
author Qiu, Yingqi
Wang, Hao
Liao, Peiyun
Xu, Binyan
Hu, Rong
Yang, Yulu
Li, Yuhua
author_facet Qiu, Yingqi
Wang, Hao
Liao, Peiyun
Xu, Binyan
Hu, Rong
Yang, Yulu
Li, Yuhua
author_sort Qiu, Yingqi
collection PubMed
description BACKGROUND: Belonging to the protein arginine methyltransferase (PRMT) family, the enzyme encoded by coactivator associated arginine methyltransferase 1 (CARM1) catalyzes the methylation of protein arginine residues, especially acts on histones and other chromatin related proteins, which is essential in regulating gene expression. Beyond its well-established involvement in the regulation of transcription, recent studies have revealed a novel role of CARM1 in tumorigenesis and development, but there is still a lack of systematic understanding of CARM1 in human cancers. An integrated analysis of CARM1 in pan-cancer may contribute to further explore its prognostic value and potential immunological function in tumor therapy. RESULTS: Based on systematic analysis of data in multiple databases, we firstly verified that CARM1 is highly expressed in most tumors compared with corresponding normal tissues, and is bound up with poor prognosis in some tumors. Subsequently, relevance between CARM1 expression level and tumor immune microenvironment is analyzed from the perspectives of tumor mutation burden, microsatellite instability, mismatch repair genes, methyltransferases genes, immune checkpoint genes and immune cells infiltration, indicating a potential relationship between CARM1 expression and tumor microenvironment. A gene enrichment analysis followed shortly, which implied that the role of CARM1 in tumor pathogenesis may be related to transcriptional imbalance and viral carcinogenesis. CONCLUSIONS: Our first comprehensive bioinformatics analysis provides a broad molecular perspective on the role of CARM1 in various tumors, highlights its value in clinical prognosis and potential association with tumor immune microenvironment, which may furnish an immune based antitumor strategy to provide a reference for more accurate and personalized immunotherapy in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12863-021-01022-w.
format Online
Article
Text
id pubmed-8761291
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87612912022-01-18 Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker Qiu, Yingqi Wang, Hao Liao, Peiyun Xu, Binyan Hu, Rong Yang, Yulu Li, Yuhua BMC Genom Data Research BACKGROUND: Belonging to the protein arginine methyltransferase (PRMT) family, the enzyme encoded by coactivator associated arginine methyltransferase 1 (CARM1) catalyzes the methylation of protein arginine residues, especially acts on histones and other chromatin related proteins, which is essential in regulating gene expression. Beyond its well-established involvement in the regulation of transcription, recent studies have revealed a novel role of CARM1 in tumorigenesis and development, but there is still a lack of systematic understanding of CARM1 in human cancers. An integrated analysis of CARM1 in pan-cancer may contribute to further explore its prognostic value and potential immunological function in tumor therapy. RESULTS: Based on systematic analysis of data in multiple databases, we firstly verified that CARM1 is highly expressed in most tumors compared with corresponding normal tissues, and is bound up with poor prognosis in some tumors. Subsequently, relevance between CARM1 expression level and tumor immune microenvironment is analyzed from the perspectives of tumor mutation burden, microsatellite instability, mismatch repair genes, methyltransferases genes, immune checkpoint genes and immune cells infiltration, indicating a potential relationship between CARM1 expression and tumor microenvironment. A gene enrichment analysis followed shortly, which implied that the role of CARM1 in tumor pathogenesis may be related to transcriptional imbalance and viral carcinogenesis. CONCLUSIONS: Our first comprehensive bioinformatics analysis provides a broad molecular perspective on the role of CARM1 in various tumors, highlights its value in clinical prognosis and potential association with tumor immune microenvironment, which may furnish an immune based antitumor strategy to provide a reference for more accurate and personalized immunotherapy in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12863-021-01022-w. BioMed Central 2022-01-16 /pmc/articles/PMC8761291/ /pubmed/35033016 http://dx.doi.org/10.1186/s12863-021-01022-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Qiu, Yingqi
Wang, Hao
Liao, Peiyun
Xu, Binyan
Hu, Rong
Yang, Yulu
Li, Yuhua
Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker
title Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker
title_full Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker
title_fullStr Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker
title_full_unstemmed Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker
title_short Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker
title_sort systematic pan-cancer landscape identifies carm1 as a potential prognostic and immunological biomarker
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761291/
https://www.ncbi.nlm.nih.gov/pubmed/35033016
http://dx.doi.org/10.1186/s12863-021-01022-w
work_keys_str_mv AT qiuyingqi systematicpancancerlandscapeidentifiescarm1asapotentialprognosticandimmunologicalbiomarker
AT wanghao systematicpancancerlandscapeidentifiescarm1asapotentialprognosticandimmunologicalbiomarker
AT liaopeiyun systematicpancancerlandscapeidentifiescarm1asapotentialprognosticandimmunologicalbiomarker
AT xubinyan systematicpancancerlandscapeidentifiescarm1asapotentialprognosticandimmunologicalbiomarker
AT hurong systematicpancancerlandscapeidentifiescarm1asapotentialprognosticandimmunologicalbiomarker
AT yangyulu systematicpancancerlandscapeidentifiescarm1asapotentialprognosticandimmunologicalbiomarker
AT liyuhua systematicpancancerlandscapeidentifiescarm1asapotentialprognosticandimmunologicalbiomarker